drugset
drugset / Trial / NCT06729593

Remdesivir for Severely Ill Inpatients With COVID-19 (An ACTIV-3b/TESICO Treatment Trial)

NCT06729593 ↗

Phase 3 Completed 87 enrolled National Institute of Allergy and Infectious Diseases (NIAID) Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections · collabGilead Sciences · collabInternational Network for Strategic Initiatives in Global HIV Trials (INSIGHT) · collabKirby Institute · collabMedical Research Council · collabPrevention and Early Treatment of Acute Lung Injury (PETAL) Network · collabUS Department of Veterans Affairs · collabUniversity of Copenhagen · collabWashington D.C. Veterans Affairs Medical Center · collab
RandomizedParallel-groupTriple-blindTreatment

Summary

This study looks at the safety and effectiveness of Remdesivir in treating COVID-19 in people who have been hospitalized with the infection and who have acute respiratory failure. Participants in the study will be treated with Remdesivir plus current standard of care (SOC), or with placebo plus current SOC.

Timeline

Start
2021-04-20
Primary completion
2022-08-22
Completion
2022-11-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Remdesivir Small molecule 100 mg Intravenous
Background Dexamethasone Small molecule — —
Background Hydrocortisone Other / unclassified — —
Background Methylprednisolone Other / unclassified — —
Background Prednisone Other / unclassified — —

Indications

COVID-19